15 Xia G, Rachfal AW, Martin AE, *et al.* Upregulation of endogenous heparin-binding EGF-like growth factor (HB-EGF) expression after intestinal ischemia/reperfusion injury. J Invest Surg 2003;16:57–63.
16 Pillai SB, Hinman CE, Luquette MH, *et al.* Heparin-binding epidermal growth factor-like growth factor protects rat intestine from ischemia/reperfusion injury. J Surg Res 1999;87:225–231.
17 Kirkland G, Paizis K, Wu LL, *et al.* Heparin-binding EGF-like growth factor mRNA is upregulated in the peri-infarct region of the remnant kidney model: *in vitro* evidence suggests a regulatory role in myofibroblast transformation. J Am Soc Nephrol 1998;9:1464–1473.
18 Iwamoto R, Yamazaki S, Asakura M, *et al.* Heparin-binding EGF-like growth factor and ErbB signaling is essential for heart function. Proc Natl Acad Sci USA 2003;100:3221–3226.
19 Jackson LF, Qiu TH, Sunnarborg SW, *et al.* Defective valvulogenesis in HB-EGF and TACE-null mice is associated with aberrant BMP signaling. EMBO J 2003;22:2704–2716.
20 Nakamura Y, Handa K, Iwamoto R, *et al.* Immunohistochemical distribution of CD9, heparin binding epidermal growth factor-like growth factor, and integrin alpha3beta1 in normal human tissues. J Histochem Cytochem 2001;49:439–444.
21 Fujino T, Hasebe N, Fujita M, *et al.* Enhanced expression of heparin-binding EGF-like growth factor and its receptor in hypertrophied left ventricle of spontaneously hypertensive rats. Cardiovasc Res 1998;38:365–374.
22 Iwabu A, Murakami T, Kusachi S, *et al.* Concomitant expression of heparin-binding epidermal growth factor-like growth factor mRNA and basic fibroblast growth factor mRNA in myocardial infarction in rats. Basic Res Cardiol 2002;97:214–222.
23 Tanaka N, Masamura K, Yoshida M, *et al.* A role of heparin-binding epidermal growth factor-like growth factor in cardiac remodeling after myocardial infarction. Biochem Biophys Res Commun 2002;297:375–381.
24 Asakura M, Kitakaze M, Takashima S, *et al.* Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. Nat Med 2002;8:35–40.
25 Shah BH, Catt KJ. A central role of EGF receptor transactivation in angiotensin II-induced cardiac hypertrophy. Trends Pharmacol Sci 2003;24:239–244.
26 Taniyama Y, Morishita R, Aoki M, *et al.* Angiogenesis and antifibrotic action by hepatocyte growth factor in cardiomyopathy. Hypertension 2002;40:47–53.
27 Li Y, Takemura G, Kosai K, *et al.* Postinfarction treatment with an adenoviral vector expressing hepatocyte growth factor relieves chronic left ventricular remodeling and dysfunction in mice. Circulation 2003;107:2499–2506.
28 Li Q, Li B, Wang X, *et al.* Overexpression of insulin-like growth factor-1 in mice protects from myocyte death after infarction, attenuating ventricular dilation, wall stress, and cardiac hypertrophy. J Clin Invest 1997;100:1991–1999.
29 Su EJ, Cioffi CL, Stefansson S, *et al.* Gene therapy vector-mediated expression of insulin-like growth factors protects cardiomyocytes from apoptosis and enhances neovascularization. Am J Physiol Heart Circ Physiol 2003;284:H1429–H1440.
30 Chen SH, Chen XH, Wang Y, *et al.* Combination gene therapy for liver metastasis of colon carcinoma *in vivo*. Proc Natl Acad Sci USA 1995;92:2577–2581.
31 Terazaki Y, Yano S, Yuge K, *et al.* An optimal therapeutic expression level is crucial for suicide gene therapy for hepatic metastatic cancer in mice. Hepatology 2003;37:155–163.
32 Aoyama T, Takemura G, Maruyama R, *et al.* Molecular mechanisms of non-apoptosis by Fas stimulation alone versus apoptosis with an additional actinomycin D in cultured cardiomyocytes. Cardiovasc Res 2002;55:787–798.
33 Ogasawara J, Watanabe-Fukunaga R, Adachi M, *et al.* Lethal effect of the anti-Fas antibody in mice. Nature 1993;364:806–809.
34 Takemura G, Kato S, Aoyama T, *et al.* Characterization of ultrastructure and its relation with DNA fragmentation in Fas-induced apoptosis of cultured cardiac myocytes. J Pathol 2001;193:546–556.
35 Toraason M, Wey H, Woolery M, *et al.* Arachidonic acid supplementation enhances hydrogen peroxide induced oxidative injury of neonatal rat cardiac myocytes. Cardiovasc Res 1995;29:624–628.
36 Villarreal FJ, Kim NN, Ungab GD, *et al.* Identification of functional angiotensin II receptors on rat cardiac fibroblasts. Circulation 1993;88:2849–2861.
37 Takemura G, Ohno M, Hayakawa Y, *et al.* Role of apoptosis in the disappearance of infiltrated, proliferated interstitial cells after myocardial infarction. Circ Res 1998;82:1130–1138.
38 Leor J, Quinones MJ, Patterson M, *et al.* Adenovirus-mediated gene transfer into infarcted myocardium: feasibility, timing, and location of expression. J Mol Cell Cardiol 1996;28:2057–2067.
39 Barr E, Carroll J, Kalynych AM, *et al.* Efficient catheter-mediated gene transfer into the heart using replication-defective adenovirus. Gene Therapy 1994;1:51–58.
40 Chu D, Sullivan CC, Weitzman MD, *et al.* Direct comparison of efficiency and stability of gene transfer into the mammalian heart using adeno-associated virus versus adenovirus vectors. J Thorac Cardiovasc Surg 2003;126:671–679.
41 Huang CY, Hao LY, Buetow DE. Insulin-like growth factor-induced hypertrophy of cultured adult rat cardiomyocytes is L-type calcium-channel-dependent. Mol Cell Biochem 2002;231:51–59.
42 Michalsky MP, Kuhn A, Mehta V, *et al.* Heparin-binding EGF-like growth factor decreases apoptosis in intestinal epithelial cells *in vitro*. J Pediatr Surg 2001;36:1130–1135.
43 Siddiqui AJ, Blomberg P, Wardell E, *et al.* Combination of angiopoietin-1 and vascular endothelial growth factor gene therapy enhances arteriogenesis in the ischemic myocardium. Biochem Biophys Res Commun 2003;310:1002–1009.